• Alias: SAR245408, XL-147
    • An orally bioavailable small molecule targeting the class I PI3K family
    • Currently in phase 2 trial for endometrial cancers, phase 1b/2 trial for hormone receptor–positive breast cancer
    • Recommended phase 2 dose: 600 mg PO daily as continuous dosing
    • Half-life: 70 to 88 hours
    • Side effects: Macular, papular rash, nausea, diarrhea, decreased appetite
    (Matulonis et al., 2015; Shapiro et al., 2015)
    Other topics in Targeted and Immunotherapy Agents